Functional and molecular evidence for expression of the renin angiotensin system and ADAM17-mediated ACE2 shedding in COS7 cells

American Journal of Physiology - Cell Physiology

Volumn 308, Issue 9, 2015, Pages C767-C777

  Grobe, Nadja ^a   Di Fulvio, Mauricio ^a   Kashkari, Nada ^a   Chodavarapu, Harshita ^a   Somineni, Hari K ^a   Singh, Richa ^a   Elased, Khalid M ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

ACE2 shedding; ADAM17; COS7; Renin angiotensin system

Indexed keywords

ADAM17 PROTEIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; CAPTOPRIL; CELL EXTRACT; DIPEPTIDYL CARBOXYPEPTIDASE; PROTEIN; RENIN; RENIN INHIBITOR; RNA; SHORT HAIRPIN RNA; TETRADECAPEPTIDE; UNCLASSIFIED DRUG; ADAM PROTEIN; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ANGIOTENSIN II; MESSENGER RNA; PEPTIDE FRAGMENT; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL CELL; ARTICLE; CELL LYSATE; COMPARATIVE STUDY; CONTROLLED STUDY; COS 7 CELL LINE; ENZYME ACTIVITY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY HOMOGENATE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STABLE TRANSFECTION; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING; ANIMAL; CHLOROCEBUS AETHIOPS; COS CELL LINE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULAR GENETICS; RNA INTERFERENCE;

CERCOPITHECUS AETHIOPS;

ADAM PROTEINS; ADAM17 PROTEIN; ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; COS CELLS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; RENIN-ANGIOTENSIN SYSTEM; RNA INTERFERENCE; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84930851465     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00247.2014     Document Type: Article

References (58)

1. Balashova N, Chang FJ, Lamothe M, Sun Q, Beuve A. Characterization of a novel type of endogenous activator of soluble guanylyl cyclase. J Biol Chem 280: 2186-2196, 2005.
2. Becker KP, Ullian M, Halushka PV. Cloning and characterization of an endogenous COS-7 cell thromboxane A2 receptor. Biochim Biophys Acta 1403: 109-114, 1998.
3. Bonde MM, Olsen KB, Erikstrup N, Speerschneider T, Lyngso C, Haunso S, Nielsen MS, Sheikh SP, Hansen JL. The angiotensin II type 1 receptor antagonist Losartan binds and activates bradykinin B2 receptor signaling. Regul Pept 167: 21-25, 2011.
4. Chan KH, Chen YH, Zhang Y, Wong YH, Dun NJ. Angiotensin-[1-12] interacts with angiotensin type I receptors. Neuropharmacology 81: 267- 273, 2014.
5. Chang SY, Chen YW, Chenier I, Tran SM, Zhang SL. Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2. Exp Diabetes Res 2011: 521076, 2011.
6. Chodavarapu H, Grobe N, Somineni HK, Salem ES, Madhu M, Elased KM. Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLoS One 8: e62833, 2013.
7. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415-472, 2000.
8. Di Fulvio M, Gomez-Cambronero J. Phospholipase D (PLD) gene expression in human neutrophils and HL-60 differentiation. J Leukoc Biol 77: 999-1007, 2005.
9. Di Fulvio M, Henkels KM, Gomez-Cambronero J. Short-hairpin RNAmediated stable silencing of Grb2 impairs cell growth and DNA synthesis. Biochem Biophys Res Commun 357: 737-742, 2007.
10. Dilauro M, Zimpelmann J, Robertson SJ, Genest D, Burns KD. Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease. Am J Physiol Renal Physiol 298: F1523-F1532, 2010.
11. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-E9, 2000.
12. Elased KM, Cunha TS, Gurley SB, Coffman TM, Morris M. New mass spectrometric assay for angiotensin-converting enzyme 2 activity. Hypertension 47: 1010-1017, 2006.
13. Filipiak KJ. Can drugs influencing the renin-angiotensin system prevent diabetes mellitus? A lesson from randomized clinical trials. Cardiol J 17: 435-436, 2010.
14. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 16: 1135-1140, 2005.
15. Ford BM, Eid AA, Gooz M, Barnes JL, Gorin YC, Abboud HE. ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice. Am J Physiol Renal Physiol 305: F323- F332, 2013.
16. Gembardt F, Grajewski S, Vahl M, Schultheiss HP, Walther T. Angiotensin metabolites can stimulate receptors of the Mas-related genes family. Mol Cell Biochem 319: 115-123, 2008.
17. Giani JF, Mayer MA, Munoz MC, Silberman EA, Hocht C, Taira CA, Gironacci MM, Turyn D, Dominici FP. Chronic infusion of angiotensin- (1-7) improves insulin resistance and hypertension induced by a highfructose diet in rats. Am J Physiol Endocrinol Metab 296: E262-E271, 2009.
18. Grobe N, Elased KM, Cool DR, Morris M. Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. Am J Physiol Endocrinol Metab 302: E1016-E1024, 2012.
19. Grobe N, Weir NM, Leiva O, Ong FS, Bernstein KE, Schmaier AH, Morris M, Elased KM. Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. Am J Physiol Cell Physiol 304: C945-C953, 2013.
20. Herrera M, Sparks MA, Alfonso-Pecchio AR, Harrison-Bernard LM, Coffman TM. Response to lack of specificity of commercial antibodies leads to misidentification of angiotensin type-1 receptor protein. Hypertension 61: e32, 2013.
21. Hofman K, Swinnen JV, Verhoeven G, Heyns W. Coactivation of an endogenous progesterone receptor by TIF2 in COS-7 cells. Biochem Biophys Res Commun 295: 469-474, 2002.
22. Iwata M, Silva Enciso JE, Greenberg BH. Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor alpha-converting enzyme. Am J Physiol Cell Physiol 297: C1318-C1329, 2009.
23. Karip E, Turu G, Supeki K, Szidonya L, Hunyady L. Cross-inhibition of angiotensin AT1 receptors supports the concept of receptor oligomerization. Neurochem Int 51: 261-267, 2007.
24. Lai ZW, Hanchapola I, Steer DL, Smith AI. Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site identification: determinants and constraints. Biochemistry 50: 5182-5194, 2011.
25. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensinconverting enzyme-2 (ACE2). J Biol Chem 280: 30113-30119, 2005.
26. Leehey DJ, Singh AK, Bast JP, Sethupathi P, Singh R. Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats. Transl Res 151: 208-216, 2008.
27. Lo CS, Liu F, Shi Y, Maachi H, Chenier I, Godin N, Filep JG, Ingelfinger JR, Zhang SL, Chan JS. Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. Am J Physiol Renal Physiol 302: F840-F852, 2012.
28. Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ, Frank GD, Inagami T, Higashiyama S, Thomas WG, Eckhart AD, Dempsey PJ, Eguchi S. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 280: 26592-26599, 2005.
29. Mizuiri S, Aoki T, Hemmi H, Arita M, Sakai K, Aikawa A. Urinary angiotensin-converting enzyme 2 in patients with CKD. Nephrology (Carlton) 16: 567-572, 2011.
30. Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, Kubo K, Fuse H, Imura Y, Kusumoto K, Nagaya H. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 336: 801-808, 2011.
31. Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, Putko B, Kassiri Z, Turner AJ, Oudit GY. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol 66: 167-176, 2014.
32. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 57: 313-370, 1977.
33. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ, Black RA. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 275: 14608-14614, 2000.
34. Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 39: 799-802, 2002.
35. Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simoes e Silva AC. The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag 4: 787-803, 2008.
36. Rioli V, Kato A, Portaro FC, Cury GK, te KK, Vincent B, Checler F, Camargo AC, Glucksman MJ, Roberts JL, Hirose S, Ferro ES. Neuropeptide specificity and inhibition of recombinant isoforms of the endopeptidase 342416 family: comparison with the related recombinant endopeptidase 342415. Biochem Biophys Res Commun 250: 5-11, 1998.
37. Ronchi FA, Irigoyen MC, Casarini DE. Association of somatic and N-domain angiotensin-converting enzymes from Wistar rat tissue with renal dysfunction in diabetes mellitus. J Renin Angiotensin Aldosterone Syst 8: 34-41, 2007.
38. Salem ES, Grobe N, Elased KM. Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am J Physiol Renal Physiol 306: F629-F639, 2014.
39. Santiago NM, Guimaraes PS, Sirvente RA, Oliveira LA, Irigoyen MC, Santos RA, Campagnole-Santos MJ. Lifetime overproduction of circulating angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension- induced cardiac dysfunction and remodeling. Hypertension 55: 889-896, 2010.
40. Santos RA, Simoes Silva AC E, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100: 8258- 8263, 2003.
41. Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y, Batlle D. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 72: 614- 623, 2007.
42. Somineni HK, Boivin GP, Elased KM. Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice. J Endocrinol 221: 235-251, 2014.
43. Tan F, Morris PW, Skidgel RA, Erdos EG. Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C). Similarity to both serine carboxypeptidase and prolylendopeptidase families. J Biol Chem 268: 16631-16638, 1993.
44. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41: 392-397, 2003.
45. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243, 2000.
46. Velez JC, Bland AM, Arthur JM, Raymond JR, Janech MG. Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes. Am J Physiol Renal Physiol 293: F398-F407, 2007.
47. Velez JC, Ierardi JL, Bland AM, Morinelli TA, Arthur JM, Raymond JR, Janech MG. Enzymatic processing of angiotensin peptides by human glomerular endothelial cells. Am J Physiol Renal Physiol 302: F1583-F1594, 2012.
48. Wang G, Lai FM, Lai KB, Chow KM, Kwan CH, Li KT, Szeto CC. Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia 51: 1062-1067, 2008.
49. Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem 280: 39353-39362, 2005.
50. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 2411. Life Sci 52: 1461-1480, 1993.
51. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F. Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int 61: 1986-1995, 2002.
52. Wysocki J, Garcia-Halpin L, Ye M, Maier C, Sowers K, Burns KD, Batlle D. Regulation of urinary ACE2 in diabetic mice. Am J Physiol Renal Physiol 305: F600-F611, 2013.
53. Xiao F, Hiremath S, Knoll G, Zimpelmann J, Srivaratharajah K, Jadhav D, Fergusson D, Kennedy CR, Burns KD. Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetes. PLoS One 7: e37649, 2012.
54. Xiao F, Zimpelmann J, Agaybi S, Gurley SB, Puente L, Burns KD. Characterization of Angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells. PLoS One 9: e85958, 2014.
55. Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.42411) in spontaneously hypertensive rats. Hypertension 19: 692-696, 1992.
56. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 43: 1120 - 1125, 2004.
57. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of angiotensin-converting enzyme 2 and Angiotensin- converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17: 3067-3075, 2006.
58. Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, Penninger JM, Scholey JW, Kassiri Z, Oudit GY. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 57: 314 - 322, 2011.